SOPH Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

20.49M

+15.56%

-0.255

+10.87%

20.07M

+12.87%

-0.235

-9.62%

20.99M

+14.56%

-0.253

-23.48%

Estimates Revision

The market is revising Upward the revenue expectations for SOPHiA GENETICS SA (SOPH) for FY2025, with the revenue forecasts being adjusted by 0.44% over the past three months. During the same period, the stock price has changed by 12.83%.

Revenue Estimates for FY2025

Revise Upward

+0.44%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+5.03%

In Past 3 Month

Stock Price

Go Up

+12.83%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast SOPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SOPH is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

7.00

Averages

7.00

High

7.00

Current: 0.000

Low

7.00

Averages

7.00

High

7.00

BTIG

Mark Massaro

Buy

maintain

$6 -> $7

2025-11-10

Reason

BTIG

Mark Massaro

Price Target

$6 -> $7

2025-11-10

maintain

Buy

Reason

BTIG analyst Mark Massaro raised the firm's price target on Sophia Genetics to $7 from $6 and keeps a Buy rating on the shares. The company delivered a solid Q3 revenue beat and raise, and this small cap name looks well-positioned to make a big move in 2026, the analyst tells investors in a research note. Management also sees signs of a recovery building in biopharma, which when added to more clinical customers coming online at higher selling prices, will mark an inflection point in revenue and margin, the firm added.

Valuation Metrics

The current forward P/E ratio for SOPHiA GENETICS SA (SOPH.O) is -4.79, compared to its 5-year average forward P/E of -4.65. For a more detailed relative valuation and DCF analysis to assess SOPHiA GENETICS SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.65

Current PE

-4.79

Overvalued PE

-1.92

Undervalued PE

-7.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.64

Current EV/EBITDA

-7.80

Overvalued EV/EBITDA

-0.39

Undervalued EV/EBITDA

-6.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.09

Current PS

3.76

Overvalued PS

12.12

Undervalued PS

0.05

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 1033.12% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SOPH News & Events

Events Timeline

No data

News

7.5

01-07PRnewswire

SOPHiA GENETICS Partners with MD Anderson to Accelerate Cancer Data Analysis

7.5

01-07Newsfilter

SOPHiA GENETICS Partners with MD Anderson to Accelerate Cancer Data Analysis

2.0

2025-12-22NASDAQ.COM

After-Hours Gains on Friday: Biotech and Genomics Stocks Demonstrate Resilience

People Also Watch

Frequently Asked Questions

What is SOPHiA GENETICS SA (SOPH) stock price today?

The current price of SOPH is 5.145 USD — it has increased 3.73 % in the last trading day.

What is SOPHiA GENETICS SA (SOPH)'s business?

SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.

What is the price predicton of SOPH Stock?

What is SOPHiA GENETICS SA (SOPH)'s revenue for the last quarter?

SOPHiA GENETICS SA revenue for the last quarter amounts to 19.46M USD, increased 22.77 % YoY.

What is SOPHiA GENETICS SA (SOPH)'s earnings per share (EPS) for the last quarter?

SOPHiA GENETICS SA. EPS for the last quarter amounts to -0.30 USD, increased 7.14 % YoY.

What changes have occurred in the market's expectations for SOPHiA GENETICS SA (SOPH)'s fundamentals?

How many employees does SOPHiA GENETICS SA (SOPH). have?

SOPHiA GENETICS SA (SOPH) has 423 emplpoyees as of January 09 2026.

What is SOPHiA GENETICS SA (SOPH) market cap?

Today SOPH has the market capitalization of 336.52M USD.